This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Dr. Paul Feldman, PhD
Chief Scientific Officer at Aktis Oncology


Paul received his PhD from the University of CA, Berkeley and then joined Glaxo Inc.. At GlaxoSmithKline Paul rose to senior vice president and was part of discovering five approved drugs. In 2015 Paul co-founded and was CEO of Phoundry Pharmaceuticals, a metabolic diseases peptide therapeutics company. Phoundry was acquired by Intarcia Therapeutics and Paul was Head of Discovery and Translational Medicine. His team discovered several peptide assets for treatment of metabolic diseases. In 2020 Paul became Chief Scientific Officer of Aktis Oncology. Aktis is focused on discovering and developing tumor specific binding miniprotein radioconjugates to treat solid-tumor cancers.

Agenda Sessions

  • Pioneering Aktis Oncology’s Miniprotein Radioconjugates